Golden said painless progressive weakness is the key to recognizing ALS, and although research still has a long way to go, ...

A biotech company based out of Massachusetts found a tremendous amount of success on Wednesday after Leerink Partners ...

Coya Therapeutics, Inc.’s COYA share price has surged by 12.31%, which has investors questioning if this is right time to ...

A groundbreaking achievement in brain-computer interface technology: an ALS patient uses a Neuralink implant to edit and narrate a YouTube video.

The third patient of Elon Musk's brain computer interface company Neuralink is using the billionaire's foul-mouthed AI ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Smith is the first non-verbal individual and only the third person globally to receive a Neuralink Brain-Chip Interface (BCI) implant.

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S.

Clene’s cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...